Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
SAB Biotherapeutics, Inc.
13G/A
SABS · 78397T202
|
8.8% |
8/14/2026
Event 6/30/2026
|
|||
| Caligan Partners LP | 8.8% | ||||
| Johnson David Edward | 8.8% | ||||
|
Avalo Therapeutics, Inc.
13G/A
AVTX · 05338F306
|
5.9% |
8/14/2026
Event 6/30/2026
|
|||
| Caligan Partners LP | 5.9% | ||||
| David Johnson | 5.9% | ||||
|
Opus Genetics, Inc.
13G/A
IRD · 67577R102
|
7.3% |
8/14/2026
Event 6/30/2026
|
|||
| Caligan Partners LP | 7.3% | ||||
| Johnson David Edward | 7.3% | ||||
|
Faeth Therapeutics, Inc.
13G/A
FTH · 81728A207
|
2.4% |
8/14/2026
Event 6/30/2026
|
|||
| Caligan Partners LP | 2.4% | ||||
| David Johnson | 2.4% | ||||
|
Cellectar Biosciences, Inc.
13G
CLRB · 15117F880
|
5.9% |
8/14/2026
Event 6/30/2026
|
|||
| Caligan Partners LP | 5.9% | ||||
| Johnson David Edward | 5.9% | ||||
|
LB Pharmaceuticals Inc
13G
LBRX · 50180M108
|
5.0% |
5/15/2026
Event 3/31/2026
|
|||
| Caligan Partners LP | 5.0% | ||||
| Johnson David Edward | 5.0% | ||||
|
Evolus, Inc.
13G/A
EOLS · 30052C107
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| Caligan Partners LP | 0% | ||||
| David Johnson | 0% | ||||
|
Anika Therapeutics, Inc.
13D/A
ANIK · 035255108
|
10.0% |
1/27/2026
Event 1/23/2026
|
|||
| Caligan Partners LP | 10.0% | ||||
| David Johnson | 10.0% | ||||
|
Verrica Pharmaceuticals Inc.
13D/A
VRCA · 92511W207
|
10.0% |
12/30/2025
Event 12/26/2025
|
|||
| Caligan Partners LP | 10.0% | ||||
| David Johnson | 10.0% | ||||
|
Y-mAbs Therapeutics, Inc.
13G/A
YMAB · 984241109
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| Caligan Partners LP | 0% | ||||
| David Johnson | 0% | ||||
|
Verrica Pharmaceuticals Inc.
13G
VRCA · 92511W108
|
10.0% |
2/12/2025
Event 12/31/2024
|
|||
| Caligan Partners LP | 10.0% | ||||
| David Johnson | 10.0% | ||||